Biotransformation of beta-endorphin and possible therapeutic implications

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Asvadi, Naghmeh H ^a   Morgan, Michael ^a   Hewavitharana, Amitha K ^a   Shaw, P Nicholas ^a   Cabot, Peter J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biotransformation; Inflammation; Opioid; Pain; Peptide; Proteomics

Indexed keywords

ANALGESIC AGENT; BETA ENDORPHIN; ENZYME INHIBITOR; OPIATE; OPIATE PEPTIDE; OPIATE RECEPTOR; PEPTIDASE; PEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANALGESIA; ARTICLE; BIOTRANSFORMATION; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NEUROMODULATION; NOCICEPTION; NONHUMAN; PAIN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 84895527826     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00018     Document Type: Article

References (45)

1. Augustyns, K., Veken, P. V. D., Senten, K., and Haemers, A. (2005). The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. 12, 971-998. doi: 10.2174/0929867053507298.
2. Binder, W., Mousa, S. A., Sitte, N., Kaiser, M., Stein, C., and Schäfer, M. (2004). Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur. J. Neurosci. 20, 92-100. doi: 10.1111/j.1460-9568.2004.03459.x.
3. Brownson, E. A., Abbruscato, T. J., Gillespie, T. J., Hruby, V. J., and Davis, T. P. (1994). Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J. Pharmacol. Exp. Ther. 270, 675-680.
4. Cabot, P. J., Carter, L., Gaiddon, C., Zhang, Q., Schäfer, M., Loeffler, J. P., et al. (1997). Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J. Clin. Invest. 100, 142-148.
5. Deakin, J. F., Doströvsky, J. O., and Smyth, D. G. (1980). Influence of N-terminal acetylation and C-terminal proteolysis on the analgesic activity of beta-endorphin. Biochem. J. 189, 501-506.
6. De Wied, D. (1979). Schizophrenia as an inborn error in the degradation of β-endorphin a hypothesis. Trends Neurosci. 2, 79-82.
7. Dray, A. (1995). Inflammatory mediators of pain. Br. J. Anaesth. 75, 125-131. doi: 10.1093/bja/75.2.125.
8. Duggan, A. W., and Fleetwood-Walker, S. M. (1993). "Opioids and sensory processing in the central nervous system," in Opioids, eds A. Herz, H. Akil and E. Simon (Berlin; Heidelberg: Springer), 731-771.
9. Finley, M. J., Happel, C. M., Kaminsky, D. E., and Rogers, T. J. (2008). Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell. Immunol. 252, 146-154. doi: 10.1016/j.cellimm.2007.09.008.
10. Franchi, S., Moretti, S., Castelli, M., Lattuada, D., Scavullo, C., Panerai, A. E., et al. (2012). Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages. Brain Behav. Immun. 26, 480-488. doi: 10.1016/j.bbi.2011.12.010.
11. Giersbergen, P. L. M. V., Lang, H. D., and Jong, W. D. (1991). Effects of dynorphin A(1-13) and of fragments of β-endorphin on blood pressure and heart rate of anesthetized rats. Can. J. Physiol. Pharmacol. 69, 327-333. doi: 10.1139/y91-050.
12. Hammonds, R. G., Nicolas, P., and Li, C. H. (1984). beta-endorphin-(1-27) is an antagonist of beta-endorphin analgesia. Proc. Natl. Acad. Sci. U.S.A. 81, 1389-1390.
13. Hemmick, L. M., and Bidlack, J. M. (1989). Beta-endorphin suppresses rat plaque-forming cell response by a non-opioid mechanism. J. Neuroimmunol. 23, 67-71.
14. Herath, H., Cabot, P., Shaw, P., and Hewavitharana, A. (2012). Study of beta endorphin metabolism in inflamed tissue, serum and trypsin solution by liquid chromatography-tandem mass spectrometric analysis. Anal. Bioanal. Chem. 402, 2089-2100. doi: 10.1007/s00216-011-5686-8.
15. Hildebrand, A., Preissner, K. T., Müller-Berghaus, G., and Teschemacher, H. (1989). A novel beta-endorphin binding protein. Complement S protein (= vitronectin) exhibits specific non-opioid binding sites for beta-endorphin upon interaction with heparin or surfaces. J. Biol. Chem. 264, 15429-15434.
16. Hiramatsu, M., Inoue, K., Ambo, A., Sasaki, Y., and Kameyama, T. (2001). Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg Ψ (CH2NH) Arg-NH2, in mice. Br. J. Pharmacol. 132, 1948-1956. doi: 10.1038/sj.bjp.0703982.
17. Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., et al. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci. 28, 20-29. doi: 10.1111/j.1460-9568.2008.06321.x.
18. Jaba, I., Tamba, B., Manolidis, G., and Mungiu, O. (2007). Variation in the analgesic activity of opioid peptide fragments in correlation with the amino acidic sequence. Cent. Eur. J. Med. 2, 417-429. doi: 10.2478/s11536-007-0036-0.
19. Kapitzke, D., Vetter, I., and Cabot, P. J. (2005). Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control. Ther Clin. Risk Manag. 1, 279-297.
20. Kovalitskaya, Y. A., and Navolotskaya, E. V. (2011). Nonopioid effect of β-endorphin. Biochemistry (Mosc.) 76, 379-393. doi: 10.1134/S0006297911040018.
21. Lewis, S. S., Hutchinson, M. R., Rezvani, N., Loram, L. C., Zhang, Y., Maier, S. F., et al. (2010). Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1β. Neuroscience 165, 569-583. doi: 10.1016/j.neuroscience.2009.10.011.
22. Lin, L., Sohar, I., Lackland, H., and Lobel, P. (2001). The human CLN2 Protein/Tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. J. Biol. Chem. 276, 2249-2255. doi: 10.1074/jbc.M008562200.
23. McKnight, A. T., Corbett, A. D., and Kosterlitz, H. W. (1983). Increase in potencies of opioid peptides after peptidase inhibition. Eur. J. Pharmacol. 86, 393-402. doi: 10.1016/0014-2999(83)90189-9.
24. Mentlein, R. (1999). Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24. doi: 10.1016/S0167-0115(99)00089-0.
25. Montiel, J.-L., Cornille, F., Roques, B. P., and Noble, F. (1997). Nociceptin/Orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. J. Neurochem. 68, 354-361. doi: 10.1046/j.1471-4159.1997.68010354.x.
26. Morgan, M., Herath, H. M. D. R., Cabot, P. J., Shaw, P. N., and Hewavitharana, A. K. (2012). Dynorphin A 1-17 biotransformation in inflamed tissue, serum and trypsin solution analysed by liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 404, 3111-3121. doi: 10.1007/s00216-012-6406-8.
27. Müller, S., and Hochhaus, G. (1995). Metabolism of dynorphin A 1-13 in human blood and plasma. Pharm. Res. 12, 1165-1170. doi: 10.1023/A:1016211910107.
28. Nicolas, P., and Choh Hao, L. (1985). Inhibition of analgesia by C-terminal deletion analogs of human β-endorphin. Biochem. Biophys. Res. Commun. 127, 649-655. doi: 10.1016/s0006-291x(85)80210-2.
29. Reed, B., Bidlack, J. M., Chait, B. T., and Kreek, M. J. (2008). Extracellular biotransformation of β-endorphin in rat striatum and cerebrospinal fluid. J. Neuroendocrinol. 20, 606-616. doi: 10.1111/j.1365-2826.2008.01705.x.
30. Rittner, H. L., Brack, A., and Stein, C. (2008). Pain and the immune system. Br. J. Anaesth. 101, 40-44. doi: 10.1093/bja/aen078.
31. Sacerdote, P., and Panerai, A. E. (1989). Analysis of the beta-endorphin structure-related activity on human monocyte chemotaxis: importance of the N-and C-terminal. Peptides 10, 565-569. doi: 10.1016/0196-9781(89)90143-5.
32. Sakurada, C., Sakurada, S., Hayashi, T., Katsuyama, S., Tan-No, K., and Sakurada, T. (2003). Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem. Pharmacol. 66, 653-661. doi: 10.1016/S0006-2952(03)00391-5.
33. Sandin, J., Nylander, I., and Silberring, J. (1998). Metabolism of β-endorphin in plasma studied by liquid chromatography-electrospray ionization mass spectrometry. Regul. Pept. 73, 67-72. doi: 10.1016/s0167-0115(97)01065-3.
34. Schreiter, A., Gore, C., Labuz, D., Fournie-Zaluski, M.-C., Roques, B. P., Stein, C., et al. (2012). Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue. FASEB J. 26, 5161-5171. doi: 10.1096/fj.12-208678.
35. Scornik, O. A., and Botbol, V. (2001). Bestatin as an experimental tool in mammals. Curr. Drug Metab. 2, 67-85. doi: 10.2174/1389200013338748.
36. Shane, R., Wilk, S., and Bodnar, R. J. (1999). Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res. 815, 278-286. doi: 10.1016/S0006-8993(98)01121-4.
37. Smart, D., Smith, G., and Lambert, D. G. (1995). Mu-opioids activate phospholipase C in SH-SY5Y human neuroblastoma cells via calcium-channel opening. Biochem. J. 305, 577-581.
38. Su, X., Joshi, S. K., Kardos, S., and Gebhart, G. F. (2002). Sodium channel blocking actions of the κ-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects. J. Neurophysiol. 87, 1271-1279.
39. Tien, L.-T., Fan, L.-W., Ma, T., Loh, H. H., and Ho, I.-K. (2004). Increased diisopropylfluorophosphate-induced toxicity in μ-opioid receptor knockout mice. J. Neurosci. Res. 78, 259-267. doi: 10.1002/jnr.20259.
40. Van Den Bergh, P., Rozing, J., and Nagelkerken, L. (1993). Identification of two moieties of beta-endorphin with opposing effects on rat T-cell proliferation. Immunology 79, 18-23.
41. Van Den Burg, E., Metz, J. R., Arends, R., Devreese, B., Vandenberghe, I., Van Beeumen, J., et al. (2001). Identification of beta-endorphins in the pituitary gland and blood plasma of the common carp (Cyprinus carpio). J. Endocrinol. 169, 271-280. doi: 10.1677/joe.0.1690271.
42. Van Ree, J. M., and De Wied, D. (1982). Behavioral effects of the beta-endorphin fragment 2-9. Life Sci. 31, 2383-2386.
43. Welch, S. P., and Dunlow, L. D. (1993). Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists: a common mechanism of action? J. Pharmacol. Exp. Ther. 267, 390-399.
44. Yamamoto, Y., Hashimoto, J.-I., Shimamura, M., Yamaguchi, T., and Hazato, T. (2000). Characterization of tynorphin, a potent endogenous inhibitor of dipeptidyl peptidaseIII. Peptides 21, 503-508. doi: 10.1016/S0196-9781(00)00174-1.
45. Zakarian, S., and Smyth, D. G. (1982). [beta]-Endorphin is processed differently in specific regions of rat pituitary and brain. Nature 296, 250-252.